SHPH

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Dollar change -0.0411
Percentage change -5.55	%

Peers: GERN MDGL ARWR ALKS BCRX BLUE PDSB CTMX AKBA ADAP

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-4.20	Insider Own	25.23%	Shs Outstand	2.95M	Perf Week	-12.30%
Market Cap	2.57M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	2.74M	Perf Month	-39.13%
Income	-9.19M	PEG	-	EPS next Q	-	Inst Own	0.81%	Short Float	2.07%	Perf Quarter	-58.82%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	27.55%	Short Ratio	0.05	Perf Half Y	-80.08%
Book/sh	-0.45	P/B	-	EPS next Y	-	ROA	-228.26%	Short Interest	0.06M	Perf Year	-81.79%
Cash/sh	0.04	P/C	16.06	EPS next 5Y	-	ROE	-427.85%	52W Range	0.72 - 4.95	Perf YTD	-80.77%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-94.84%	ROI	-	52W High	-85.85%	Beta	0.37
Dividend TTM	-	Quick Ratio	0.16	Sales past 5Y	0.00%	Gross Margin	-	52W Low	-2.93%	ATR (14)	0.09
Dividend Ex-Date	-	Current Ratio	0.16	EPS Y/Y TTM	-33.42%	Oper. Margin	-	RSI (14)	27.61	Volatility	8.80% 8.84%
Employees	8	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	-	Target Price	-
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	-74.23%	Payout	-	Rel Volume	0.04	Prev Close	0.74
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	1.09M	Price	0.70
SMA20	-17.22%	SMA50	-37.13%	SMA200	-72.01%	Trades		Volume	39,659	Change	-5.55%

Nov-26-24 09:00AM	Shuttle Pharma Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma as UVA Cancer Center Doses Its First Patient (GlobeNewswire)
Nov-13-24 05:00PM	Shuttle Pharma Provides Third Quarter 2024 Corporate Update (GlobeNewswire)
Oct-29-24 09:05PM	Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) +35.34%
04:05PM	Shuttle Pharma Pays Off Senior Secured Convertible Note (GlobeNewswire)
09:00AM	Shuttle Pharma Doses First Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma (GlobeNewswire)
04:05PM	Loading…
Oct-28-24 04:05PM	Shuttle Pharma Completes Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma (GlobeNewswire) +6.40%
09:00AM	Shuttle Pharmaceuticals to Present at the 2024 ThinkEquity Conference on Wednesday, October 30, 2024 (GlobeNewswire)
Sep-16-24 09:00AM	Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma (GlobeNewswire)
Sep-11-24 01:00PM	Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing (ACCESSWIRE)
Sep-05-24 09:00AM	Shuttle Pharma Announces Issuance of U.S. Patent for Selective Histone Deacetylase Inhibitors for the Treatment of Human Disease (GlobeNewswire) -8.44%
Sep-04-24 04:15PM	Shuttle Pharma Provides Second Quarter 2024 Corporate Update (GlobeNewswire) +9.00%
Aug-28-24 09:00AM	Shuttle Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire) -13.02%
Aug-26-24 04:10PM	Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1) (GlobeNewswire) +7.54% -13.45%
Aug-14-24 04:10PM	Shuttle Pharma Ready to Enroll Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma (GlobeNewswire) +6.63%
Jul-19-24 09:00AM	Shuttle Pharma's Selective HDAC Inhibitor Exhibits ATM Activation and Modulation of ER Expression Resulting in Substantial Growth Inhibition of Estrogen Receptor Positive Breast Cancer Cells, as Reported in PLOS ONE (GlobeNewswire)
09:00AM	Loading…
Jun-18-24 09:00AM	Shuttle Pharma Appoints Timothy Lorber as Chief Financial Officer (GlobeNewswire) -8.09%
May-22-24 04:15PM	Shuttle Pharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024 (GlobeNewswire)
May-14-24 09:00AM	Shuttle Pharma Provides First Quarter 2024 Corporate Update (GlobeNewswire)
May-13-24 09:53PM	SHPH Stock Earnings: Shuttle Pharmaceuticals Reported Results for Q1 2024 (InvestorPlace)
Apr-29-24 09:00AM	Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV (ACCESSWIRE)
Apr-23-24 04:15PM	Shuttle Pharmaceuticals to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024 (GlobeNewswire)
Apr-03-24 09:00AM	Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on April 4, 2024 (GlobeNewswire)
07:00AM	Presenting on the Emerging Growth Conference 69 Day 2 on April 4 Register Now (GlobeNewswire)
Apr-02-24 07:00AM	Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now (GlobeNewswire)
Mar-22-24 09:00AM	Shuttle Pharma Provides Fourth Quarter 2023 Corporate Update (PR Newswire)
Mar-06-24 07:00AM	Presenting on the Emerging Growth Conference 68 Day 2 on March 7 Register Now (GlobeNewswire) +7.44%
Mar-05-24 09:00AM	Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on March 6, 2024 (GlobeNewswire)
07:00AM	Presenting on the Emerging Growth Conference 68 Day 1 on March 6 Register Now (GlobeNewswire)
Feb-13-24 08:00AM	Shuttle Pharma Announces Its Intent to Pursue a Rights Offering (PR Newswire)
Jan-23-24 04:30PM	Shuttle Pharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024 (PR Newswire)
09:00AM	Loading…
Jan-08-24 09:00AM	Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma (PR Newswire) -12.40%
Dec-11-23 09:00AM	Shuttle Pharmaceuticals Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma (PR Newswire)
Dec-06-23 07:00AM	Presenting on the Emerging Growth Conference 65 Day 2 on December 7th Register Now (GlobeNewswire) +5.10%
Dec-05-23 07:00AM	Presenting on the Emerging Growth Conference 65 Day 1 on December 6th Register Now (GlobeNewswire)
Nov-30-23 09:00AM	Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on December 7, 2023 (PR Newswire)
Nov-14-23 09:00AM	Shuttle Pharmaceuticals Provides Third Quarter 2023 Corporate Update (PR Newswire)
Oct-31-23 09:00AM	Shuttle Pharma Advances Prostate Cancer Predictive Biomarker Program Through Exclusive License Agreement (PR Newswire)
Oct-10-23 09:00AM	Shuttle Pharma to Participate in the Lytham Partners Fall 2023 Investor Conference (PR Newswire)
Sep-25-23 09:00AM	Shuttle Pharma Announces Results of Pre-IND Meeting with FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma (PR Newswire)
Sep-13-23 09:00AM	Shuttle Pharma Participates in Hampton University Proton Therapy Institute Prostate Cancer & Men's Health Fair (PR Newswire)
Sep-11-23 09:00AM	Shuttle Pharma Expands Patent Coverage on HDAC Inhibitor Platform (PR Newswire)
Aug-29-23 09:00AM	Shuttle Pharma's Selective HDAC6 Inhibitor Shown to Stimulate Innate Immune Response in Pre-clinical Studies, as Reported in Molecular Cancer Therapeutics (PR Newswire) +5.79%
Aug-15-23 09:00AM	Shuttle Pharmaceuticals Provides Second Quarter 2023 Corporate Update (PR Newswire) -5.74%
Aug-03-23 09:00AM	Shuttle Pharmaceuticals Completes Manufacturing of Active Pharmaceutical Ingredient (API) for Use in Clinical Trial (PR Newswire)
May-26-23 09:00AM	Shuttle Pharmaceuticals Provides First Quarter 2023 Corporate Update (PR Newswire)
May-17-23 09:00AM	Shuttle Pharmaceuticals to Participate in the Lytham Partners Spring 2023 Investor Conference (PR Newswire)
Mar-22-23 09:00AM	Shuttle Pharmaceuticals Enters Research Agreement with Georgetown University for Testing of Small Molecule Radiation Sensitizers and Immune Activation Candidates (PR Newswire)
Mar-15-23 09:00AM	Shuttle Pharmaceuticals Provides Fiscal Year 2022 Corporate Update (PR Newswire)
Mar-09-23 09:00AM	Shuttle Pharmaceuticals Engages UI Pharmaceuticals for Formulation and Clinical Batch Manufacture of Ropidoxuridine for Brain Tumor Clinical Trial (PR Newswire)
Feb-23-23 09:00AM	Shuttle Pharmaceuticals Expands Laboratory Space to Advance Drug Development Pipeline and Diagnostic Capabilities (PR Newswire) -8.21%
Jan-26-23 04:15PM	Shuttle Pharmaceuticals to Present at Lytham Partners Investor Select Conference on January 31 (PR Newswire) -16.12%
Jan-17-23 09:00AM	Shuttle Pharmaceuticals to Ring Nasdaq Opening Bell on Wednesday, January 18, 2023 (PR Newswire) -10.68%
Jan-12-23 04:15PM	Shuttle Pharmaceuticals Announces Private Placement of $4.3 Million of Senior Secured Convertible Note and Warrants (PR Newswire) +32.20%
Jan-10-23 09:00AM	Shuttle Pharmaceuticals Manuscript Published in Cancer Research Communications (PR Newswire)
Dec-06-22 09:00AM	Shuttle Pharmaceuticals Manuscript Published in Cancer Research Communications (PR Newswire) -22.00%
Nov-15-22 09:00AM	Shuttle Pharmaceuticals Provides Third Quarter 2022 Corporate Update (PR Newswire) +5.26%
Nov-03-22 09:00AM	Shuttle Pharmaceuticals Engages Theradex Oncology in Preparation for Clinical Study (PR Newswire)
Nov-01-22 09:00AM	Shuttle Pharmaceuticals Appoints Bette Jacobs to its Board of Directors (PR Newswire) -7.25%
Sep-20-22 09:00AM	Shuttle Pharmaceuticals Enters into Manufacturing Agreement for Ropidoxuridine (PR Newswire) -11.20%
Sep-15-22 08:30AM	Shuttle Pharmaceuticals Awarded New HDAC Inhibitor Patents for Cancer Treatment (PR Newswire) -55.65%
Sep-09-22 05:05PM	Why Shares of Shuttle Pharmaceuticals Jumped 160.4% This Week (Motley Fool) +26.14%
Sep-06-22 09:00AM	Shuttle Pharmaceuticals Announces Closing of Initial Public Offering (PR Newswire) +91.28%
Aug-31-22 01:20PM	Shuttle Pharmaceuticals Commences Trading on Nasdaq Under Ticker Symbol "SHPH" (PR Newswire)
Aug-30-22 04:40PM	Shuttle Pharmaceuticals Announces Pricing of Initial Public Offering (PR Newswire)

Shuttle Pharmaceuticals Holdings, Inc. is a clinical stage pharmaceutical company, which engages in the development of novel therapies for cancer. It also offers cancer treatments with surgery, radiation therapy, chemotherapy, and immunotherapy. The company was founded by Anatoly Dritschilo, Mira Jung, and Milton Brown on December 18, 2012 and is headquartered in Gaithersburg, MD.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Shuttle Pharmaceuticals Holdings Inc

Upgrade your FINVIZ experience